Work

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

Year: 2013

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(13)70294-8

Authors: David I Quinn, Catherine M Tangen, Maha Hussain, Primo N Lara, Amir Goldkorn, Carol M Moinpour, Mark G Garzotto, Philip C Mack, Michael A Carducci, J Paul Monk, Przemyslaw W Twardowski, Peter J Van Veldhuizen, Neeraj Agarwal, Celestia S Higano, Nicholas J Vogelzang, Ian M Thompson

Institutions: University of Southern California, USC Norris Comprehensive Cancer Center, SWOG Cancer Research Network, University of Michigan, University of California, Davis, Portland VA Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, The Ohio State University, City Of Hope National Medical Center, City of Hope, University of Kansas, University of Utah, Seattle Cancer Care Alliance, University of Washington, Comprehensive Cancer Centers of Nevada, The University of Texas at San Antonio Health Science Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G1033243903, G1165598027, G117886320, G1202672505, G1216887118, G1257575315, G1312097577, G1331445602, G1343089328, G1375689152, G1391839138, G1469275664, G1545560008, G1790576020, G1911575068, G1958973285, G1985252453, G2043432835, G2057923966, Scott & White Community Clinical Oncology Program, G2160369479, G2201816905, G2237949143, G2276667821, G2345882982, G2419449687, G2435896781, G2485941414, G2562936776, G2679961467, G268786457, MAREK'S DISEASE VIRUS--TRANSFORMATION AND ONCOGENESIS, G2733372321, G2750730928, COLUMBIA UNIVERSITY SOUTHWEST ONCOLOGY GROUP PROGRAM, Ozark Health Ventures, LLC dba Cancer Research for the Ozarks, GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM, SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER, G3126600779, G3239274266, G3242537740, Southeast Cancer Control Consortium, Inc, G3295642875, G3334379738, G3337849518, G3484997517, G3497039781, G3521018462, City of Hope Southwest Oncology Group Clinical Trials, G36541222, G3705794112, G3710026009, G3737421695, G379387698, G3939550896, G3996959562, G413878341, G425646771, Southwest Oncology Group, G444114835, Southwest Oncology Group, G4499432180, G4527800867, SOUTHWEST ONCOLOGY GROUP, SOUTHWEST ONCOLOGY GROUP, G5187432406, G5264753430, G543303160, G5566132837, G5765316850, SOUTHWEST ONCOLOGY GROUP, G6723594983, G6782300252, G7222907299, G7230571265, CENTRAL ILLINOIS COMMUNITY CLINICAL ONCOLOGY PROGRAM, SOUTHWEST ONCOLOGY GROUP STUDY, G7520596819, Virginia Mason Community Clinical Oncology Program, G776903742, Nevada Cancer Research foundation-Community Clinical Oncology Program, G7860541851, G7926913928, G8006406963, G8036334546, Eastern Cooperative Oncology Group Operations Office, G8413228103, G860872252, SOUTHWEST ONCOLOGY GROUP, G8740717309, G8777682367, PARTICIPATE AS MEMBER OF SOUTHWEST ONCOLOGY GROUP, G8937348795, Cancer Center Support Grant P30, University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG), G933283670, G937543590, G964706321, G971274320

OpenAlex ID: W2113046540

FWCI: 19.22

Cites: 40

Cited by: 161

Related to: 10